AI assistant
Sending…
Avidity Biosciences, Inc. — Director's Dealing 2020
Jun 17, 2020
30894_dirs_2020-06-16_dbd77dab-a0b6-463f-9a2b-4eb6277a5d70.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2020-06-16
Reporting Person: ELI LILLY & Co (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-16 | Common Stock | C | 2169396 | — | Acquired | 2169396 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-06-16 | Series C Preferred Stock | $ | C | 4576342 | Disposed | Common Stock (2169396) | Direct |
Footnotes
F1: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering.
More from Avidity Biosciences, Inc.
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27